3-Bromopyruvate overcomes cetuximab resistance in human colorectal cancer cells by inducing autophagy-dependent ferroptosis

Colorectal cancer (CRC) remains a leading cause of cancer-related death worldwide. Cetuximab, in combination with chemotherapy, is effective for treating patients with wild-type KRAS/BRAF metastatic CRC (mCRC). However, intrinsic or acquired drug resistance often limits the use of cetuximab. In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Mu, Mingchao, Zhang, Qin, Zhao, Chenye, Li, Xiaopeng, Chen, Zilu, Sun, Xuejun, Yu, Junhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581902/
https://www.ncbi.nlm.nih.gov/pubmed/37558749
http://dx.doi.org/10.1038/s41417-023-00648-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581902/
https://www.ncbi.nlm.nih.gov/pubmed/37558749
http://dx.doi.org/10.1038/s41417-023-00648-5

Ejemplares similares